Copyright
©The Author(s) 2019.
World J Stem Cells. Apr 26, 2019; 11(4): 222-235
Published online Apr 26, 2019. doi: 10.4252/wjsc.v11.i4.222
Published online Apr 26, 2019. doi: 10.4252/wjsc.v11.i4.222
Table 2 Summary of mesenchymal stem cells/platelet-rich plasma clinical trials in osteoarthritis patients from 2012 to 2018
Defect type | MSC type | Delivery system | Type of study | Results | Ref. |
OA | AD-MSC | MSCs/PRP | Case series (n = 21); Final follow-up: 6 mo | Significant positive changes at MRI | Bui et al[55], 2014 |
OA | AD-MSC | MSCs/PRP | Case series (n = 18); Final follow-up: 24.3 mo | Clinical improvement; Function and pain improvement at 24.3 mo | Koh et al[52], 2013 |
OA | AD-MSC | MSCs/PRP | Case series (n = 30); Final follow-up: 24 mo | Reducing pain and improving function in patients with knee OA | Koh et al[56], 2012 |
OA | AD-MSC | MSCs/PRP | Case series (n = 21); Final follow-up: 24 mo | Function and pain improvement as compared with PRP only | Koh et al[57], 2014 |
OA | Autologous SVF | SVF/PRP | Case series (n = 21); Final follow-up: 24 mo | All patients’ scores of pain improved to > 96; and quality of life scores to > 93 | Gibbs et al[58], 2015 |
OA | Autologous SVF | SVF/PRP | Case series (n = 10); Final follow-up: 24 mo | Cartilage thickness improvement | Bansal et al[59], 2017 |
- Citation: Wang AT, Feng Y, Jia HH, Zhao M, Yu H. Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review. World J Stem Cells 2019; 11(4): 222-235
- URL: https://www.wjgnet.com/1948-0210/full/v11/i4/222.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v11.i4.222